Markers to sensibility and relapse on IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models cisplatin-treated

xlomafota13 shared this article with you from Inoreader Markers to sensibility and relapse on IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models cisplatin-treated Via histochem Acta Histochem. 2022 Jan 13;124(2):151849. doi: 10.1016/j.acthis.2022.151849. Online ahead of print. ABSTRACT The complexity of different components of tumor stroma poses huge challenges for therapies targeting the neuroblastoma (NB) microenvironment. The present study aimed to evaluate platinum-based response in IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models. For this, we evaluated mRNA expression of heat shock proteins HSPA1A, HSPB1, TRAP1, HSPA1AL, HSPD1, and DNA damage repair gene ERCC1. After treatment, residual cells were grafted on CAM (chicken chorioallantoic membrane) to evaluate the growth capability and histological paraffin sections were made to assess Ki-67 and HER-2 proteins by immunofluorescence. Our results showed that cisplatin induces mRNA downregulation of Heat Shock Proteins and ERCC1 in IMR-32 cells cultured in 2D or 3D models. In addition, the cisplatin-treatment approach increased HER-2 expression in residual IMR-32 cells grafted on the CAM. Therefore, these insights provide many advances in neuroendocrine tumor biology and knowledge about cisplatin-response in neuroblastoma. PMID:35033934 | DOI:10.1016/j.acthis.2022.151849 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Frequency of success and complications of primary endoscopic third ventriculostomy in infants with obstructive hydrocephalous

xlomafota13 shared this article with you from Inoreader Frequency of success and complications of primary endoscopic third ventriculostomy in infants with obstructive hydrocephalous Via leak of cerebrospinal fluid Pak J Med Sci. 2022 Jan-Feb;38(1):267-270. doi: 10.12669/pjms.38.1.4097. ABSTRACT OBJECTIVES: To determine the success rate and complications of primary endoscopic third ventri-culostomy (ETV) in infants with obstructive hydrocephalous. METHODS: This case series was conducted at the Department of Neurosurgery, Medical and Teaching Institute, Lady Reading Hospital Peshawar from July 2016 to June 2018. All consecutive patients with age less than one year who underwent ETV for primary obstructive hydrocephalous, of both gender, were included in the study. The patients were followed up to six months after surgery. The data was entered in a specially designed Performa. Patients' data was analyzed using SPSS version 21.0. RESULTS: We had total 21 patients with age less than one year during the study period. Male patients were 11 (52.4%). Success rate of ETV at six months of follow up was 12 (57.1%). Post-op complications observed were i n 9.52% (2/21) cases. One patient had cerebrospinal fluid CSF) leak and the other had significant bleed. CONCLUSION: ETV is successful in 57.1% of infants with obstructive type of hydrocephalous. The post op complications in case of ETV are lower than Ventriculo-peritoneal shunts. Therefore, ETV can be offered to infants having obstructive hydrocephalous. PMID:35035437 | PMC:PMC8713220 | DOI:10.12669/pjms.38.1.4097 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A Rare Cause of Secondary Otalgia

xlomafota13 shared this article with you from Inoreader Message: PrivacyPrivacy Skip to main content Intended for healthcare professionals SAGE Journals Search search-icon Browse Resources Access Options: You are not signed in to your personal profile Sign In You are not signed in via an institution Institution You are not authenticated via a society Society Cart Ear, Nose & Throat Journal 1.697 Impact Factor 5-Year Impact Factor 1.745 Journal Indexing & Metrics » Journal Home Browse Journal Journal Info Stay Connected Submit Paper Search Article Menu Download PDF [PDF] Open EPUB Full Article Content List Significance Statement ORCID iDs References Figures & Tables Article Metrics Cite Share Request Permissions Related Articles A Rare Cause of Secondary Otalgia Show all authors Evropi Forozidou, MD, Nikolaos Tsetsos, MD, MSc, Paraskevi Karamitsou, MD, MSc, ... First Published January 17, 2022 Research Article https://doi.org/10.1177/01455613221075226 Article information Open AccessCreative Commons Attribution, Non Commercial 4.0 License Significance Statement Secondary otalgia is defined as pain felt in the ear although originating from a non-otologic source. The complex innervation of ear structures makes the identification of the responsible region a challenging procedure. The 2 most common causes of secondary otalgia are the temporomandibular joint dysfunction and dental infections. We present a rare case of secondary otalgia caused by a foreign body hidden deeply in the lateral surface of the tongue. A 61-year-old male ironworker presented to our emergency Ear, Nose and Throat department complaining about left otalgia accompanied by difficulty in swallowing. Symptoms had started 1 week before in his work environment. The patient was prescribed a 5-day course of antibiotics with ciprofloxacin ear drops combined with painkillers by his family doctor without, however, any signs of improvement. His past medical history was otherwise normal. A thorough clinical examination combined with otomicroscopy was unremarkable for any ear pathology. Fiberoptic nasolaryngoscopy and laboratory tests were also normal. Inspection of the oral cavity showed no signs of inflammation; however, a tender area on the left lateral surface of the tongue was noted. After careful observation, a tiny hole was recognized in the same area (Figure 1). An exploration of the area under local anesthesia was conducted and a metallic iron bar of approximately 1.5 cm in length was removed (Figure 2). Symptoms were completely subsided and the patient remained pain free at 1-week follow-up. figure Figure 1. Oral cavity inspection. Recognition of the painful area on the left lateral surface of the tongue. figure Figure 2. The extracted foreign body. A metallic iron bar. Otalgia is a rather common symptom seen in the primary care setting with many diverse causes. Primary otalgia is related to clinical entities affecting the outer, middle, and inner ear.1 Inflections such as acute or chronic media otitis, external otitis, folliculitis, mastoiditis, and myringitis constitute the most common etiologic factors. Cerumen obstruction, ear neoplasms, and trauma may also be responsible for primary otalgia. The origin of primary otalgia is almost always easy to be established with otomicroscopy or radiographic imaging.2 On the other hand, when the cause of pain cannot be localized to the affected ear, it is referred to as secondary otalgia. There is a considerable overlap between the innervation of the ear and the related areas in the head and neck. Innervation of the ear structures comprises multiple lower cranial, upper cervical, and peripheral nerves. They innervate the spine, skull base, salivary glands, pharynx, larynx, oral cavity, orbits, face, paranasal sinuses, and deep neck spaces. The most common causes of secondary otalgia are temporomandibular joint syndrome and dental infections. Additionally, other potential causes of otalgia are Bell's palsy, salivary gland disorders, pharyngitis, tonsillitis, oral disorders, and cervical osteoarthritis.2,3 Clinicians should be aware that otalgia could be the primary symptom of a head and neck malignancy. Therefore, a thorough clinical examination of the whole head and neck area is imperative to exclude neoplasms.3,4 Inflammation, trauma, and neoplasms of the tongue often cause secondary otalgia via the trigeminal (CN V) and the glossopharyngeal nerve (CN IX). The third branch of the trigeminal, the mandibular nerve (V3), is a mixed nerve. The auriculotemporal nerve is a branch of the V3 that provides sensation to the anterosuperior pinna, anterior external auditory canal, and the anterior lateral aspect of the tympanic membrane. Other branches include the lingual, buccal, and inferior alveolar nerves that provide sensory innervation to the oral cavity, the floor of the mouth, and the anterior two-thirds of the tongue.5 The glossopharyngeal nerve (CN IX) directly innervates the inner surface of the tympanic membrane as well as the middle ear cavity through sensory fibers of the tympanic nerve (Jacobson nerve). It also provides mixed innervation to the posterior third of the tongue.6 Secondary otalgia may be caused from anywhere along the course of this nerve. In cases that thorough clinical investigation fails to establish the source of otalgia, a computed tomography or magnetic resonance imaging studies should be considered to define the diagnosis.5 Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. ORCID iDs Nikolaos Tsetsos https://orcid.org/0000-0003-1884-6824 Konstantinos Garefis https://orcid.org/0000-0003-3905-5650 Alexandros Poutoglidis https://orcid.org/0000-0002-4591-8347 References 1. Neilan, RE, Roland, PS. Otalgia. Med Clin North Am. 2010;94:96171. Google Scholar | Crossref 2. Norris, CD, Koontz, NA. Secondary Otalgia: Referred Pain Pathways and Pathologies. AJNR Am J Neuroradiol. 2020;41(12):2188-2198. Google Scholar | Crossref | Medline 3. Earwood, JS, Rogers, TS, Rathjen, NA. Ear pain: diagnosing common and uncommon causes. Am Fam Physician. 2018;97(1):20-27. Google Scholar | Medline 4. Charlett, SD, Coatesworth, AP. Referred otalgia: a structured approach to diagnosis and treatment. Am J Med Sci Med. 2017;5(3):56-61. Google Scholar 5. Scarbrough, TJ, Day, TA, Williams, TE, et al. Referred otalgia in head and neck cancer: a unifying schema. Am J Clin Oncol. 2003;26:e157-e162. Google Scholar | Crossref | Medline 6. Naraev, BG, Linthicum, FH. Traumatic neuroma of the tympanic (Jacobson's) nerve as a possible cause of otalgia. Otolaryngol Head Neck Surg. 2008;138:735-737. Google Scholar | SAGE Journals View Abstract SAGE Recommends Also from SAGE Publishing CQ LibraryAmerican political resourcesopens in new tab Data PlanetA universe of dataopens in new tab Lean LibraryIncrease the visibility of your libraryopens in new tab SAGE Business CasesReal-world cases at your fingertipsopens in new tab SAGE CampusOnline skills and methods coursesopens in new tab SAGE KnowledgeThe ultimate social science libraryopens in new tab SAGE Research MethodsThe ultimate methods libraryopens in new tab SAGE VideoStreaming video collectionsopens in new tab SAGE Journals About Privacy Policy Terms of Use Contact Us Help Accessibility Browse Health Sciences Life Sciences Materials Science & Engineering Social Sciences & Humanities Journals A-Z Discipline Hubs Resources Authors Editors Reviewers Librarians Researchers Societies Opportunities Advertising Reprints Content Sponsorships Permissions Microsites Ear, Nose & Throat Journal ISSN: 0145-5613 Online ISSN: 1942-7522 Copyright © 2022 by SAGE Publications A Rare Cause of Secondary Otalgia Via ear nose throat Ear Nose Throat J. 2022 Jan 17:1455613221075226. doi: 10.1177/01455613221075226. Online ahead of print. NO ABSTRACT PMID:35037504 | DOI:10.1177/01455613221075226 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Benefit on daily listening with technological advancements: comparison of basic and premium category hearing aids

xlomafota13 shared this article with you from Inoreader Benefit on daily listening with technological advancements: comparison of basic and premium category hearing aids Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2022 Jan 17. doi: 10.1007/s00405-021-07240-3. Online ahead of print. ABSTRACT PURPOSE: The aim of the study was to compare the user-rated benefit of two categories of hearing aids, mainly the basic and premium categories of hearing aids. METHODS: A questionnaire was administered on 102 hearing aids users (47 basic and 55 premium category users) with severity of hearing loss ranging from mild to moderately severe sensorineural hearing loss. The questionnaire administered was divided into mainly seven subscales which included speech intelligibility in quiet and in noise, ease of communication, the efficiency of noise reduction, localization, quality of music perception and cost effectiveness. The effect of duration of daily usage of hearing aids on performance among these different subscales was also assessed. RESULTS: Ease of communication was rated better by premium hearing aid users, whereas the cost effectiveness was rated to be better by basic users. There was no significant difference observed between performances of basic versus premium category of hearing aids in other listening domains assessed. There was no significant difference in any of the listening domains with daily usage duration for both categories of hearing aid users. CONCLUSION: The users of premium category devices revealed better ease of communication in daily environments, whereas performance of these devices on other listening domains remains questionable. Cost effectiveness was reported to be better by the users of basic hearing aids. A prospective and controlled paired series comparison of hearing aid performance needs to be performed to confirm these findings. PMID:35038028 | DOI:10.1007/s00405-021-07240-3 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Recommendations to protect patients with cancer against the Omicron variant

xlomafota13 shared this article with you from Inoreader Message: Préconisations pour protéger les patients de la filière oncologique face au variant OmicronRecommendations to protect patients with cancer against the Omicron variant Author links open overlay panelJérômeBarrière1GérardZalcman2LaurentFignon3NathanPeiffer-Smadja4ClarisseAudigier-Valette5MichelCarles6 https://doi.org/10.1016/j.bulcan.2021.12.007Get rights and content La protection contre le SARS-CoV-2 des patients suivis pour cancer sous traitement antinéoplasique est un enjeu prioritaire de la communauté oncologique depuis le début de la pandémie. Cet objectif s'est concrétisé en France par des actions fortes et rapides : la sanctuarisation « COVID-free » dès mars 2020 des services de chimiothérapie, l'accès prioritaire dès janvier 2021 [[1], [2]] à la vaccination et l'autorisation dès avril 2021 d'une troisième dose vaccinale précoce (DGS urgent avril 21) en cas de facteurs de risque d'immunodépression. Nous avons récemment proposé un arbre décisionnel en fonction du taux d'anticorps (Ac) anti-Spike (S) après la deuxième dose, dans le but d'identifier les patients pouvant bénéficier d'une troisième dose précoce, en priorisant ceux ayant un taux < 260 BAU/mL [3]. Il s'agissait là de permettre un schéma vaccinal complet accéléré pour répondre au variant Delta [4]. L'émergence en Europe [5] et dans le monde, fin 2021, du variant Omicron à forte contagiosité impose une réponse rapide. Ce variant est caractérisé par un échappement immunitaire partiel à important, à la fois contre l'immunité post-infectieuse, post-vaccinale et contre les anticorps monoclonaux anti-SARS-CoV-2, qui est lié à de nombreuses mutations de la protéine S [[6], [7]]. Plusieurs raisons justifient cette urgence. D'une part, l'émergence d'Omicron s'est partout traduite à ce jour par la disparition rapide des autres variants en circulation. C'est donc la souche qui menace aujourd'hui les patients y compris oncologiques. D'autre part, l'efficacité de la réponse immunitaire liée soit à une infection préalable par d'autres souches, soit à la vaccination, semble fragilisée par Omicron [[7], [8]]. Enfin, la neutralisation du SARS-Cov2 obtenue par les combinaisons d'anticorps monoclonaux anti-SARS-CoV-2 disponibles (casirivimab/imdevimab et tixagevimab/cilgavimab) apparaît sur les données préliminaires de tests de neutralisation in vitro nulle pour les premiers et très incertaine pour les derniers [9]. Or, ces anticorps, lorsqu'ils étaient administrés en prophylaxie permettaient de diminuer significativement le risque d'infection à SARS-CoV-2 (étude PROVENT, [10]) et, lorsqu'ils étaient administrés en traitement précoce, le risque de COVID-19 sévère [11]. Nous alertons la communauté oncologique sur le risque supplémentaire de COVID-19 grave lié à l'émergence du variant Omicron, pour les patients suivis pour cancer. Prenant en compte les données disponibles en population générale, ce risque est majeur dans la population oncologique, comme pour d'autres populations immunodéprimées (thérapies ciblées anti-CD20 par exemple). Néanmoins, la quantification précise de ce risque en termes d'hospitalisation et de décès n'est pas connue à ce jour. Afin d'anticiper cette nouvelle menace, à la fois du point de vue du risque de contagiosité que de l'échappement à la réponse immune, nos six propositions sont les suivantes : Proposition 1 : recommander une troisième dose vaccinale pour tous avec contrôle du taux résiduel d'Ac anti-S à trois mois. Face au variant Omicron, les données déjà disponibles objectivent une diminution de l'efficacité vaccinale plus rapide que par rapport au variant Delta, avec manifestement une protection accrue du booster (dose 3) [12]. Le niveau d'Ac anti-S obtenu après une dose 3 a été rapporté environ neuf fois supérieur qu'après une dose 2 dans la population générale [13]. En oncologie les données sont encore trop peu nombreuses mais certains patients semblent tirer nettement bénéfice du boosteravec des taux d'Ac anti-S sous chimiothérapie qui dépassent les taux atteints après deux doses [14], qui rappelons-le demeurent significativement inférieurs à la population générale à quatre semaines de la dose 2 [15]. Recommander la dose 3 précocement (à trois ou quatre mois de la dose 2) pour tous les patients oncologiques désormais (certains n'ont à ce jour encore uniquement reçu deux doses), et administrer une dose 4 pour ceux ayant déjà fait leur dose 3 depuis trois à quatre mois en fonction du taux d'Ac anti-S résiduel, apparaît opportun pour tenter de protéger au mieux ces patients face au variant Omicron qui nécessite un taux d'anticorps protecteurs plus élevés que face aux précédents variants. Ayant montré que les traitements par anticorps anti-CD20 constituent un facteur de risque majeur d'absence de réponse humorale à la vaccination chez les patients atteints de leucémie lymphoïde chronique ou lymphome, même avec une troisième dose vaccinale précoce [16], la dose 4 a cependant très peu de chances d'être efficace dans ce sous-groupe de patients. Proposition 2 : retenir le seuil de 1000 BAU/mL comme taux d'Ac anti-S pour une dose vaccinale additionnelle (dose 4). Si le taux d'anti-S mesuré est < 1000 BAU/mL, une dose additionnelle est proposée. Ce seuil correspond en effet à celui obtenu environ trois à quatre mois après dose 2 dans une population sans comorbidité [17] et à qui désormais une dose 3 est proposée de manière anticipée pour conférer rapidement une protection sérologique optimale face à Omicron. Ce seuil pourrait donc être la valeur retenue pour la surveillance des patients immunodéprimés, en particulier les patients oncologiques, afin de proposer une dose vaccinale additionnelle, c'est-à-dire une dose 4. Proposition 3 : prescription en prophylaxie primaire pré-exposition de l'association d'anticorps monoclonaux tixagevimab/cilgavimab (EVUSHELD®, AstraZeneca), pour les patients sans séroconversion après dose 3–4. Cette association d'anticorps à demi-vie longue demeure efficace in vitro sur le variant Delta. Lorsque Omicron sera le variant majoritaire, le risque de perte de sensibilité décrit in vitro devrait alors faire prioriser l'anticorps sotrovimab (XEVUDY®, GSK) [18] semblant moins affecté in vitro par les mutations d'Omicron [9] même si les données d'efficacité clinique de l'association tixagevimab/cilgavimab face à Omicron pourraient s'avérer suffisantes, avec possiblement la nécessité d'une deuxième administration précoce pour maintenir un taux élévé des anticorps dans le sang ou d'une augmentation de la dose. Actuellement seuls les patients atteints d'hémopathies lymphoïdes ou ayant reçu une greffe de cellules souches hématopoïétiques sont éligibles en oncologie à la procédure d'accès précoce. Il nous semble opportun d'élargir à l'ensemble de la population oncologique sous traitement actif les indications, face au risque omicron, en l'absence de séroconversion après un schéma vaccinal à quatre doses. Le seuil de 264 BAU/mL actuellement seuil de prescription reste à préciser face au variant Omicron et pourrait nécessiter un relèvement à 1000 BAU/mL. Proposition 4 : vaccination complète (trois doses) pour les proches des patients sous chimiothérapie. Nous recommandons également la vaccination des enfants de cinq à onze ans en contact de parents immunodéprimés, en accord avec la plupart des sociétés savantes pédiatriques mondiales et les autorités américaines (FDA) et européennes (EMA) du médicament. Proposition 5 : port d'un masque de protection de type Filtering Face Piece type 2 (FFP2/N95) pour les patients en cours de traitement actif, dont certains (avec cancer pulmonaire, hémopathie lymphoïde…) ont un risque de décès de 30 % ou plus en cas de contamination, dans les lieux avec du public. De récentes données comparatives en conditions expérimentales évaluent une protection individuelle supérieure par rapport au port de masques chirurgicaux [19]. Le gain peut apparaître cependant limité si le port des masques chirurgicaux était bien respecté par tous, mais cette condition apparaît peu réaliste dans les lieux avec public (cinéma, transports en commun etc.) ou encore lors des transports en VSL/ambulance, voire lors des séances de chimiothérapie en salle commune. La protection d'un masque de type FFP2 nous apparaît ainsi être une recommandation basée sur le principe de précaution (accord d'experts) en période de forte circulation virale d'un agen t pathogène très contagieux pour protéger une population immunodéprimée. Ces masques représentent un surcoût non négligeable par rapport aux masques dits chirurgicaux simples, eux remboursés. Nous recommandons donc de manière rapide leurs remboursements sur prescription médicale. Proposition 6 : favoriser si disponibilité l'inclusion des patients suivis pour une néoplasie dans les essais thérapeutiques innovants que ce soit en prophylaxie primaire ou post-exposition, en cas de PCR positive en ciblant les anticorps monoclonaux ou thérapies antivirales à venir telles que l'association PF-07321332 et ritonavir (PAXLOVID®, Pfizer) dont les données d'efficacité contre le variant Omicron, ou dans une population immunodéprimée ne sont pas encore connues. En conclusion, la mise en œuvre de ces six propositions est de nature à protéger au mieux les patients suivis pour cancer, en particulier ceux en soins actifs, avec des données suffisantes pour formuler des recommandations complètes associant plusieurs mesures de protection qui prennent en compte le risque d'inefficacité vaccinale. Dans un contexte de reprise épidémique avec un nouveau variant hautement contagieux et échappant au moins partiellement à l'immunité acquise, nous n'avons pas le temps d'attendre des études à plus large échelle. Pour les patients immunodéprimés, c'est une menace immédiate dès janvier 2022 à laquelle nous devons apporter une réponse rapide, qui s'adaptera aux futures informations dès qu'elles seront disponibles. Financement aucun. Déclaration de liens d'intérêts M. Carles, N. Peiffer-Smadja et L. Fignon déclarent ne pas avoir de liens d'intérêts. Références [1] J.P. Spano, F. Barre-Sinoussi, M.P. Kieny, A.G. Marcelin, J.Y. Blay Vaccination anti COVID-19 pour les personnes souffrant de cancer : un impératif médical et éthique [COVID-19 vaccination for cancer patients: Medical and ethical need] Bull Cancer, 108 (3) (2021), pp. 225-227, 10.1016/j.bulcan.2021.02.001 [French. Epub 2021 Feb 16] ArticleDownload PDFView Record in ScopusGoogle Scholar [2] J. Barrière, C. Audigier-Valette, D. Borchiellini, B. Hoch, O. Castelnau, E. François, et al. Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement [We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment] Bull Cancer, 108 (4) (2021), pp. 341-342, 10.1016/j.bulcan.2021.02.003 French. Epub 2021 Mar 5 ArticleDownload PDFView Record in ScopusGoogle Scholar [3] J. Barrière, M. Carles, C. Audigier-Valette, D. Re, A. Zoubir, B. Seitz-Polski, et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position paper Eur J Cancer (2021), 10.1016/j.ejca.2021.12.011 [S0959804921012752] Google Scholar [4] J. Barrière, D. Re, F. Peyrade, M. Carles Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer Eur J Cancer, 154 (2021), pp. 66-72, 10.1016/j.ejca.2021.06.008 ArticleDownload PDFView Record in ScopusGoogle Scholar [5] Weekly epidemiological update: Omicron variant of concern (VOC)–week 50 (data as of 19 December 2021). https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-50-data-19-december-2021. Google Scholar [6] V.M. Ferré, N. Peiffer-Smadja, B. Visseaux, D. Descamps, J. Ghosn, C. Charpentier Omicron SARS-CoV-2 variant: what we know and what we don't Anaesth Crit Care Pain Med, 41 (1) (2021), p. 100998, 10.1016/j.accpm.2021.100998 Google Scholar [7] J.R.C. Pulliam, C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M.J. Groome, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa medRxiv (2021) [2021.11.11.21266068] Google Scholar [8] L. Lu, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients Clin Infect Dis (2021), 10.1093/cid/ciab1041 [ciab1041] Google Scholar [9] D. Planas, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization (2021), 10.1101/2021.12.14.472630 http://biorxiv.org/lookup/doi/10.1101/2021.12.14.472630 Google Scholar [10] "AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US". AstraZeneca (Press release). 2021. Retrieved 15 October 2021. Google Scholar [11] D.M. Weinreich, S. Sivapalasingam, T. Norton, S. Ali, H. Gao, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 N Engl J Med, 385 (23) (2021), p. e81, 10.1056/NEJMoa2108163 CrossRefView Record in ScopusGoogle Scholar [12] H. Gruell, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant (2021), 10.1101/2021.12.14.21267769 http://medrxiv.org/lookup/doi/10.1101/2021.12.14.21267769 Google Scholar [13] D.H. Canaday, O.A. Oyebanji, E. White, D. Keresztesy, M. Payne, D. Wilk, et al. Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination medRxiv [Preprint] (2021), 10.1101/2021.12.07.21267179 [2021.12.07.21267179] Google Scholar [14] V. Gounant, et al. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses J Thorac Oncol (2021), 10.1016/j.jtho.2021.10.015 [S155608642103286X] Google Scholar [15] J. Barrière, et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors Ann Oncol, 32 (2021), pp. 1053-1055 ArticleDownload PDFView Record in ScopusGoogle Scholar [16] D. Re, et al. Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies (2021), 10.1101/2021.07.18.21260669 http://medrxiv.org/lookup/doi/10.1101/2021.07.18.21260669 Google Scholar [17] A. Israel, Y. Shenhar, I. Green, E. Merzon, A. Golan-Cohen, A.A. Schäffer, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection medRxiv [Preprint] (2021), 10.1101/2021.08.19.21262111 [2021.08.19.21262111] Google Scholar [18] A. Gupta, Y. Gonzalez-Rojas, E. Juarez, M. Crespo Casal, J. Moya, D.R. Falci, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab N Engl J Med, 385 (21) (2021), pp. 1941-1950, 10.1056/NEJMoa2107934 CrossRefView Record in ScopusGoogle Scholar [19] G. Bagheri, B. Thiede, B. Hejazi, O. Schlenczek, E. Bodenschatz An upper bound on one-to-one exposure to infectious human respiratory particles Proc Natl Acad Sci U S A, 118 (49) (2021), 10.1073/pnas.2110117118 [e2110117118] Google Scholar View Abstract © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. Recommended articles Linkage and association of PAX7 polymorphisms (rs742071, rs766325, and rs4920520) with the risk of non-syndromic cleft lip with/without cleft palate: A systematic review and meta-analysis Meta Gene, Volume 31, 2022, Article 101007 Purchase PDFView details Quand évoquer une maladie héréditaire du métabolisme devant des troubles de conscience? Journal Européen des Urgences et de Réanimation, Volume 28, Issue 1, 2016, pp. 39-41 Purchase PDFView details Two methodologies of the rendezvous procedure to establish ureteral continuity from a delayed ureteral leak following pelvic surgery Surgical Oncology, Volume 40, 2022, Article 101697 Purchase PDFView details 12Next Citing articles (0) Elsevier logo About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. RELX group home page Provide feedback Recommendations to protect patients with cancer against the Omicron variant Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 11:S0007-4551(21)00685-8. doi: 10.1016/j.bulcan.2021.12.007. Online ahead of print. NO ABSTRACT PMID:35031126 | DOI:10.1016/j.bulcan.2021.12.007 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Anterior Cervical Discectomy and Fusion Using Zero-P System for Treatment of Cervical Spondylosis: A Meta-Analysis

xlomafota13 shared this article with you from Inoreader Anterior Cervical Discectomy and Fusion Using Zero-P System for Treatment of Cervical Spondylosis: A Meta-Analysis Via Traditional dysphagia therapy Pain Res Manag. 2021 Dec 16;2021:3960553. doi: 10.1155/2021/3960553. eCollection 2021. ABSTRACT OBJECTIVE: The current study aimed to explore the efficacy of Zero profile intervertebral fusion system (Zero-P) and traditional anterior plate cage system (PC) in the treatment of cervical spondylotic myelopathy (CSM). Further, the present study evaluated effects of the treatments on medical security, height of intervertebral disc, adjacent-level ossification development (ALOD), and adjacent segmentation disease (ASD) through a systematic retrospective analysis. METHODS: Studies on Zero-P system and traditional anterior plate cage system for ACDF in the treatment of CSM were searched in PubMed, Web of Science, Ovid, Embase, and Cochrane Library databases. Two independent researchers screened articles, extracted data, and evaluated the quality of the articles based on the inclusion and exclusion criteria of the current study. RevMan5.3 softwa re was used for meta-analysis following the guidelines of Cochrane collaboration network. Cervical curvature, interbody fusion rate, preoperative and postoperative disc height index (DHI), fusion cage sinking rate, postoperative dysphagia, ASD, ALOD, and loosening of screw were compared between the two groups. RESULTS: A total of 17 literatures were included in the present study, including 6 randomized controlled trials and 11 observational studies. The studies comprised a total of 1204 patients with CSM, including 605 patients in the Zero-P system group (Zero-P group) and 599 patients in the traditional animal plate cage group (PC group). Results of this meta-analysis showed that postoperative dysphagia [OR = 0.40, CI (0.28, 95% 0.58), P < 0.00001], ALOD [OR = 0.09, CI (0.02, 95% 0.39), P = 0.001], ASD [OR = 0.42, CI (0.20, 95% 0.86), P = 0.02], and screw loosening [OR = 0.20, CI (0.08, 95% 0.52), P = 0.0009] of the Zero-P group were significant ly lower compared with the PC group. On the other hand, preoperative cervical curvature [WMD = -0.23, CI (-1.38, 95% 0.92), P = 0.69], postoperative cervical curvature [WMD = -0.38, CI (-1.77, 95% 1.01), P = 0.59], cage sinking rate [OR = 1.41, CI [0.52, 95% 3.82], P = 0.50], intervertebral fusion rate [OR = 0.76, CI (0.27, 95% 2.48), P = 0.38], preoperative DHI [WMD = -0.04, CI (-0.14, 95% 0.22), P = 0.65], and postoperative DHI [WMD = 0.06, CI (-0.22, 95% 0.34), P = 0.675] were not significantly different between the two groups. CONCLUSION: It was evident that the Zero-P system used in ACDF is superior compared with the traditional anterior plate cage system in postoperative dysphagia, avoiding ALOD, ASD, and screw loosening. PMID:34956433 | PMC:PMC8702348 | DOI:10.1155/2021/3960553 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Interpretable Machine Learning–Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study

xlomafota13 shared this article with you from Inoreader Interpretable Machine Learning–Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study Via Journal of Neurological Surgery Part B: Skull Base J Neurol Surg B Skull Base DOI: 10.1055/s-0041-1740621 Purpose Transsphenoidal surgery (TSS) for pituitary adenomas can be complicated by the occurrence of intraoperative cerebrospinal fluid (CSF) leakage (IOL). IOL significantly affects the course of surgery predisposing to the development of postoperative CSF leakage, a major source of morbidity and mortality in the postoperative period. The authors trained and internally validated the Random Forest (RF) prediction model to preoperatively identify patients at high risk for IOL. A locally interpretable model-agnostic explanations (LIME) algorithm is employed to elucidate the main drivers behind each machine learning (ML) model prediction. Methods The data of 210 patients who underwent TSS were collected; first, risk factors for IOL were identified via conventional statistical methods (multivariable logistic regression). Then, the authors trained, optimized, and audited a RF prediction model. Results IOL reported in 45 patients (21.5%). The recursive feature selection algorithm identified the following variables as the most significant determinants of IOL: Knosp's grade, sellar Hardy's grade, suprasellar Hardy's grade, tumor diameter (on X, Y, and Z axes), intercarotid distance, and secreting status (nonfunctioning and growth hormone [GH] secreting). Leveraging the predictive values of these variables, the RF prediction model achieved an area under the curve (AUC) of 0.83 (95% confidence interval [CI]: 0.78; 0.86), significantly outperforming the multivariable logistic regression model (AUC = 0.63). Conclusion A RF model that reliably identifies patients at risk for IOL was successfully trained and internally validated. ML-based prediction models can predict events that were previously judged nearly unpredictable; their deployment in clinical practice may result in improved patient care and reduced postoperative morbidity and healthcare costs. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.